{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:25:34Z","timestamp":1791300334877,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,7]]},"DOI":"10.7759\/cureus.16978","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T16:32:06Z","timestamp":1628353926000},"source":"Crossref","is-referenced-by-count":8,"title":["Non-melanoma Skin Cancers in Patients on Hydroxyurea for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Divya R","family":"Gavini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhairya J","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prutha H","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davuluri","family":"Uma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/jlac.18691500212","article-title":"Ueber den Hydroxylharnstoff","volume":"150","author":"Dresler WF","year":"1869","unstructured":"Dresler WF, Stein R. Ueber den Hydroxylharnstoff. Justus Liebigs Ann Chem. 1869, 150:242-52. 10.1002\/jlac.18691500212","journal-title":"Justus Liebigs Ann Chem"},{"key":"ref2","article-title":"An overview of the clinical experience with hydroxyurea","volume":"19","author":"Donehower RC","year":"1992","unstructured":"Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol. 1992, 19:11-9.","journal-title":"Semin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.10","article-title":"Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders","volume":"11","author":"Spivak JL","year":"2011","unstructured":"Spivak JL, Hasselbalch H. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther. 2011, 11:403-14. 10.1586\/era.11.10","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann PT","year":"2015","unstructured":"McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015, 14:1749-58. 10.1517\/14740338.2015.1088827","journal-title":"Expert Opin Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu PU","year":"2009","unstructured":"Ogbogu PU, Bochner BS, Butterfield JH, et al.. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009, 124:1319-25.e3. 10.1016\/j.jaci.2009.09.022","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/247553031117a00302","article-title":"Hydroxyurea for the treatment of Psoriasis including in HIV-infected Individuals: a review","volume":"17","author":"Lee ES","year":"2011","unstructured":"Lee ES, Heller MM, Kamangar F, Park K, Liao W, Koo J. Hydroxyurea for the treatment of Psoriasis including in HIV-infected Individuals: a review. Psoriasis Forum. 2011, 17:180-7. 10.1177\/247553031117a00302","journal-title":"Psoriasis Forum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15302","article-title":"Hydroxyurea: a reappraisal of its cutaneous side effects and their management","volume":"60","author":"Bulte CA","year":"2020","unstructured":"Bulte CA, Hoegler KM, Kutlu \u00d6, Khachemoune A. Hydroxyurea: a reappraisal of its cutaneous side effects and their management. Int J Dermatol. 2020, 60:810-7. 10.1111\/ijd.15302","journal-title":"Int J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.320","article-title":"Hydroxyurea associated cutaneous lesions: a case report","volume":"6","author":"Simeonovski V","year":"2018","unstructured":"Simeonovski V, Breshkovska H, Duma S, Dohcheva-Karajovanov I, Damevska K, Nikolovska S. Hydroxyurea associated cutaneous lesions: a case report. Open Access Maced J Med Sci. 2018, 6:1458-61. 10.3889\/oamjms.2018.320","journal-title":"Open Access Maced J Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11653","article-title":"Aggressive Merkel cell carcinoma after Janus kinase inhibitor Ruxolitinib for polycythemia vera","volume":"33","author":"Rastrelli M","year":"2019","unstructured":"Rastrelli M, Ferrazzi B, Tropea S, et al.. Aggressive Merkel cell carcinoma after Janus kinase inhibitor Ruxolitinib for polycythemia vera. In Vivo. 2019, 33:1667-9. 10.21873\/invivo.11653","journal-title":"In Vivo"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103061","article-title":"Risks of solid and lymphoid malignancies in patients with myeloproliferative neoplasms: clinical implications","volume":"12","author":"Brabrand M","year":"2020","unstructured":"Brabrand M, Frederiksen H. Risks of solid and lymphoid malignancies in patients with myeloproliferative neoplasms: clinical implications. Cancers (Basel). 2020, 12:3061. 10.3390\/cancers12103061","journal-title":"Cancers (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui T","year":"2019","unstructured":"Barbui T, Ghirardi A, Masciulli A, et al.. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019, 33:1996-2005. 10.1038\/s41375-019-0487-8","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002614","article-title":"Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study","volume":"135","author":"De Stefano V","year":"2020","unstructured":"De Stefano V, Ghirardi A, Masciulli A, et al.. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood. 2020, 135:381-6. 10.1182\/blood.2019002614","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.879127","article-title":"Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan","volume":"55","author":"Mehta J","year":"2014","unstructured":"Mehta J, Wang H, Fryzek JP, Iqbal SU, Mesa R. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma. 2014, 55:2368-74. 10.3109\/10428194.2013.879127","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher D","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010, 8:336-41. 10.1016\/j.ijsu.2010.02.007","journal-title":"Int J Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN","volume":"87","author":"Antonioli E","year":"2012","unstructured":"Antonioli E, Guglielmelli P, Pieri L, et al.. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol. 2012, 87:552-4. 10.1002\/ajh.23160","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13043","article-title":"Nonmelanoma skin cancer associated with Hydroxyurea treatment: overview of the literature and our own experience","volume":"32","author":"Cantisani C","year":"2019","unstructured":"Cantisani C, Kiss N, Naqeshbandi AF, et al.. Nonmelanoma skin cancer associated with Hydroxyurea treatment: overview of the literature and our own experience. Dermatol Ther. 2019, 32:e13043. 10.1111\/dth.13043","journal-title":"Dermatol Ther"},{"key":"ref17","article-title":"Second malignancies in Philadelphia-negative myeloproliferative neoplasms-single-center experience","volume":"34","author":"Kissova J","year":"2014","unstructured":"Kissova J, Ovesna P, Penka M, Bulikova A, Kiss I. Second malignancies in Philadelphia-negative myeloproliferative neoplasms-single-center experience. Anticancer Res. 2014, 34:2489-96.","journal-title":"Anticancer Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113900","article-title":"Drug-related cutaneous adverse events in Philadelphia chromosome-negative myeloproliferative neoplasms: a literature review","volume":"21","author":"Malato A","year":"2020","unstructured":"Malato A, Rossi E, Palumbo GA, Guglielmelli P, Pugliese N. Drug-related cutaneous adverse events in Philadelphia chromosome-negative myeloproliferative neoplasms: a literature review. Int J Mol Sci. 2020, 21:3900. 10.3390\/ijms21113900","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1179\/102453308X316022","article-title":"Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution","volume":"13","author":"Radaelli F","year":"2008","unstructured":"Radaelli F, Onida F, Rossi FG, et al.. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology. 2008, 13:195-202. 10.1179\/102453308X316022","journal-title":"Hematology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.11.059","article-title":"Hydroxyurea-associated squamous dysplasia","volume":"51","author":"Sanchez-Palacios C","year":"2004","unstructured":"Sanchez-Palacios C, Guitart J. Hydroxyurea-associated squamous dysplasia. J Am Acad Dermatol. 2004, 51:293-300. 10.1016\/j.jaad.2003.11.059","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1081","article-title":"Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia","volume":"6","author":"Santoro C","year":"2017","unstructured":"Santoro C, Sperduti I, Latagliata R, et al.. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. Cancer Med. 2017, 6:1233-9. 10.1002\/cam4.1081","journal-title":"Cancer Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.827788","article-title":"Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea","volume":"55","author":"Verner E","year":"2014","unstructured":"Verner E, Forsyth C, Grigg A. Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. Leuk Lymphoma. 2014, 55:1139-43. 10.3109\/10428194.2013.827788","journal-title":"Leuk Lymphoma"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000247631","article-title":"Rapid development of multiple squamous-cell carcinomas during chronic granulocytic leukemia","volume":"183","author":"Disdier P","year":"1991","unstructured":"Disdier P, Harle JR, Grob JJ, Weiller-Merli C, Magalon G, Weiller PJ. Rapid development of multiple squamous-cell carcinomas during chronic granulocytic leukemia. Dermatologica. 1991, 183:47-8. 10.1159\/000247631","journal-title":"Dermatologica"},{"key":"ref24","article-title":"Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease","volume":"137","author":"Chaine B","year":"2001","unstructured":"Chaine B, Neonato MG, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol. 2001, 137:467-70.","journal-title":"Arch Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12282","article-title":"Incidence and prevalence of non-melanoma skin cancer in Australia: A systematic review","volume":"56","author":"Perera E","year":"2015","unstructured":"Perera E, Gnaneswaran N, Staines C, Win AK, Sinclair R. Incidence and prevalence of non-melanoma skin cancer in Australia: A systematic review. Australas J Dermatol. 2015, 56:258-67. 10.1111\/ajd.12282","journal-title":"Australas J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26194","article-title":"Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug","volume":"118","author":"Latagliata R","year":"2012","unstructured":"Latagliata R, Spadea A, Cedrone M, et al.. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer. 2012, 118:404-9. 10.1002\/cncr.26194","journal-title":"Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0945-3","article-title":"Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN","volume":"35","author":"Stegelmann F","year":"2021","unstructured":"Stegelmann F, Wille K, Busen H, et al.. Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. Leukemia. 2021, 35:628-31. 10.1038\/s41375-020-0945-3","journal-title":"Leukemia"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/0027-5107(79)90164-7","article-title":"Single-strand breaks in DNA during repair of UV-induced damage in normal human and xeroderma pigmentosum cells as determined by alkaline DNA unwinding and hydroxylapatite chromatography: effects of hydroxyurea, 5-fluorodeoxyuridine and 1-beta-D-arabinofuranosylcytosine on the kinetics of repair","volume":"59","author":"Erixon K","year":"1979","unstructured":"Erixon K, Ahnstr\u00f6m G. Single-strand breaks in DNA during repair of UV-induced damage in normal human and xeroderma pigmentosum cells as determined by alkaline DNA unwinding and hydroxylapatite chromatography: effects of hydroxyurea, 5-fluorodeoxyuridine and 1-beta-D-arabinofuranosylcytosine on the kinetics of repair. Mutat Res. 1979, 59:257-71. 10.1016\/0027-5107(79)90164-7","journal-title":"Mutat Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.14025","article-title":"Frequent clones of p53-mutated keratinocytes in normal human skin","volume":"93","author":"Jonason AS","year":"1996","unstructured":"Jonason AS, Kunala S, Price GJ, et al.. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A. 1996, 93:14025-9. 10.1073\/pnas.93.24.14025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/372773a0","article-title":"Sunburn and p53 in the onset of skin cancer","volume":"372","author":"Ziegler A","year":"1994","unstructured":"Ziegler A, Jonason AS, Leffell DJ, et al.. Sunburn and p53 in the onset of skin cancer. Nature. 1994, 372:773-6. 10.1038\/372773a0","journal-title":"Nature"},{"key":"ref31","article-title":"Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion","volume":"1","author":"Brash DE","year":"1996","unstructured":"Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. 1996, 1:136-42.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.241353198","article-title":"Escaping the stem cell compartment: sustained UVB exposure allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations","volume":"98","author":"Zhang W","year":"2001","unstructured":"Zhang W, Remenyik E, Zelterman D, Brash DE, Wikonkal NM. Escaping the stem cell compartment: sustained UVB exposure allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations. Proc Natl Acad Sci U S A. 2001, 98:13948-53. 10.1073\/pnas.241353198","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/63285-non-melanoma-skin-cancers-in-patients-on-hydroxyurea-for-philadelphia-chromosome-negative-myeloproliferative-neoplasms-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:13Z","timestamp":1707507193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/63285-non-melanoma-skin-cancers-in-patients-on-hydroxyurea-for-philadelphia-chromosome-negative-myeloproliferative-neoplasms-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.16978","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,7]]}}}